Extended Data Fig. 8: Cell viability assessment of ELOVL6i treated cells across human cancer cell lines expressing WT or mutant KRAS variants.
From: ELOVL6 activity attenuation induces mutant KRAS degradation
Cell viability was measured after a 7-day treatment with ELOVL6i at the indicated concentrations from three biological replicates. Data are represented as mean ± s.d.
